What Compagel (Heparin, Levomenthol, Hydroxyethyl Salicylate) Treats: Main Uses and Benefits

Compagel is relevant for easing symptoms related to localized inflammatory and painful states, primarily through supportive effects on physical discomfort. The core therapeutic domain for this combination is often used to help manage symptom clusters that interfere with daily functioning associated with localized soft tissue injuries and superficial vascular disorders.

Its use is commonly associated with helping to ease symptoms related to physical discomfort, such as swelling, pain, and bruising that may follow acute or episodic changes like sports injuries, accidental trauma, or localized inflammatory issues. The product's components are relevant for easing symptoms associated with edema and hematoma, a supportive role that may be part of symptomatic management. Additionally, Hydroxyethyl Salicylate contributes to easing symptoms related to physical discomfort through its analgesic and anti-inflammatory properties, while Levomenthol contributes a cooling and mild local anesthetic sensation.

The gel is commonly used in situations involving minor sprains, strains, contusions, and the management of superficial thrombophlebitis. The product is applied across domains where additional symptomatic support is needed, which helps ease the overall symptom burden and assists with maintaining functional stability during episodes of heightened discomfort.

---

Quick Fact: Support for Symptoms Related to Tired Legs

The cooling and soothing sensation of Levomenthol is often applied in scenarios where symptoms of physical discomfort arise from prolonged standing or minor superficial venous issues, helping to ease the sensation of heaviness and fatigue.

Who can and cannot use Compagel (Heparin, Levomenthol, Hydroxyethyl Salicylate)?

The eligibility for Compagel is defined by its authorization as a veterinary medicinal product for a specific species, as documented by regulatory authorities. The official information strictly governs who is approved to use the medicine and under what conditions.

Populations and Conditions for Use

Classification	Regulatory Statement (Official Use)
Approved Target	Use is exclusively permitted for the horse species.
Absolute Prohibition	Use is contraindicated for non-target species (e.g., humans, dogs).

Contraindications and Restrictions

Compagel must not be used in the following circumstances, according to the official prescribing information:

• Hypersensitivity: Contraindicated if there is a known allergy to any of the active ingredients (Heparin Sodium, Levomenthol, Hydroxyethyl Salicylate) or any excipients.
• Skin Integrity: Application is prohibited on broken skin, open wounds, or any fresh or encrusted skin lesions.
• Reproductive Status: Use is not recommended in mares that are pregnant or lactating.
• Food Safety: It is prohibited for use in mares that are producing milk intended for human consumption.

Interactions with other medicines and products

Official Interaction Scope

The regulatory interaction profile for Compagel is established by its topical route of administration and confirmed pharmacokinetic data. Official government drug labels consistently document that systemically therapeutic concentrations of the active components, particularly Heparin, are not reached following application to the skin. This finding is central to the interpretation of the official interaction section.

Interaction Type
Documented Drug–Drug Interactions	None documented in official product labeling.
Documented Metabolic Interactions	None documented. No warnings regarding CYP enzyme effects are specified.
Documented Transporter Interactions	None documented. No information on P-gp, OATP, or BCRP interactions is specified.
Documented Food, Alcohol, or Herbal Interactions	None documented. No warnings or restrictions for co-use are included in official documents.

Regulatory Classification and Restrictions

Official regulatory documents do not assign specific severity classifications to interactions, as no systemic interactions are formally listed. Consequently, the labeling includes no mandatory restrictions regarding co-administration with other medicinal products due to systemic risk, and no timing-based separation requirements are specified.

Resulting Interaction Structure

The product's official interaction structure is defined by the absence of specific warnings within the regulatory labeling. The documentation affirms that because systemically therapeutic concentrations of the components are not absorbed into the bloodstream, the regulatory authorities have not imposed formal restrictions on combining this topical gel with other systemic medicines based on pharmacokinetic or pharmacodynamic interaction risks. This structure dictates the complete official interaction profile for this combination preparation.

How Compagel (Heparin, Levomenthol, Hydroxyethyl Salicylate) Works

Compagel's action is governed by three distinct, complementary pharmacological mechanisms that influence peripheral nociceptive signaling, the local inflammatory cascade, and microcirculatory fluid dynamics.

Core Mechanistic Domains

Levomenthol acts as an agonist on the Transient Receptor Potential Cation Channel Subfamily M Member 8 ( TRPM8) in sensory nerve endings. This activation triggers an ion flux, generating a cooling signal that modulates or overrides local transmission within nociceptive pathways, initiating peripheral sensory modulation.

Hydroxyethyl Salicylate is metabolized to Salicylic Acid, a non-selective inhibitor of Cyclooxygenase ( COX) enzymes. By blocking the COX pathway, the drug reduces the synthesis of pro-inflammatory prostaglandins locally. This mechanism reduces the biochemical mediators of vasodilation and increased vascular permeability, contributing to a modulation of the inflammatory cascade.

Heparin engages the microcirculatory system by acting as a potentiator of the natural anticoagulant Antithrombin-III ( ATIII). This accelerates the inactivation of localized clotting factors, primarily Factor Xa and Thrombin. This action suppresses fibrin formation, which contributes to the reabsorption and dispersal of localized extravasated fluid and blood components from the application site.

Compagel is an officially registered veterinary medicinal product (gel) intended exclusively for use on horses. The regulatory instructions for its proper use detail the administration route, dosing constraints, and specific application conditions, which must be followed by the person administering the gel.

Administration Guidelines (For Horses)

Usage Domain	Official Regulatory Instruction
Route of Administration	Topical use (cutaneous use) to the intact skin.
Standard Dosing	Up to a total daily quantity of 50 g gel per day is applied using fingertip pressure onto the affected area.
Frequency and Duration	Applied multiple times a day, as long as the total daily quantity does not exceed 50 g. The duration is according to the veterinary surgeon's instructions until signs and symptoms resolve.

Application Requirements

Before application, the area to be treated must be clean and dry. The gel must be applied only to intact skin and should not be used on open wounds, broken skin, or mucous membranes.

Population-Specific Constraints

The product is not recommended for use in horses during pregnancy and lactation due to the lack of sufficient safety data. It is prohibited for use in mares producing milk intended for human consumption.

Research evidence / Overview of studies for Compagel (Heparin, Levomenthol, Hydroxyethyl Salicylate)

Evidence for Use in Acute Soft Tissue Injuries (Sprains, Strains, and Contusions)

Research examining the use of topical gels for acute injuries often involves short-term, randomized controlled trials (RCTs). Studies were conducted to explore how outcomes related to physical discomfort change over time, and were focused on adults who had experienced localized blunt trauma, such as minor strains, sprains, or contusions, usually evaluated within the first week of trauma. Specifically, studies monitored the evolution of pain severity using patient-reported outcomes, objective changes in tenderness, and the measurement of swelling (edema) and bruising (hematoma) over defined time intervals. The research landscape includes findings from studies on the gel's active component categories, such as topical salicylates and heparin preparations.

Evidence for Symptomatic Relief in Localized Edema and Superficial Vascular Issues

Topical treatments were also evaluated in conditions characterized by fluctuating or episodic manifestations, such as localized fluid accumulation and discomfort linked to superficial vein issues. Research examined treatments like topical Heparin preparations through randomized controlled trials and reviews, primarily in adult populations. Studies explored outcomes reflecting daily functioning and patient-reported outcomes describing perceived discomfort. Research involving topical Heparin preparations explored whether measurements of pain and swelling severity were observed to vary between active treatment and control groups over the study period.

What Remains Uncertain About the Research for Compagel

The research evidence remains limited for the specific, three-active component formulation (Heparin, Levomenthol, and Hydroxyethyl Salicylate) compared to research available for single-active-ingredient topical treatments. A central limitation is the modest sample sizes and the limited number of studies focusing on the precise three-way combination. Follow-up durations were typically short-term, generally ranging from a few days to a few weeks, meaning that long-term effects are not fully established. Comparative evidence is lacking, and certainty remains low in certain areas.

Key Studies & References

1. Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain
2. Summary of Product Characteristics (SPC) - Compagel gel for horses (Veterinary Medicines Directorate - UK)

Common questions about Compagel (Heparin, Levomenthol, Hydroxyethyl Salicylate) (FAQ)

---

Q: Does Compagel feel hot or cold when applied to the skin?

Official documents state that the Levomenthol component generates a cooling signal on the skin, which is the basis of this component's action. However, a temporary local burning sensation is also reported as an occasional reaction in official safety documents.

---

Q: Is Compagel intended for use on chronic pain or just sudden injuries?

Official documents indicate the product is generally purposed for the symptomatic management of acute, localized inflammatory conditions, such as sprains and contusions. The supporting research evidence focuses on these sudden injuries and typically evaluates outcomes over short-term periods.

---

Q: Is there a limit to how long a person should continuously use Compagel?

Regulatory instructions state that the product should be applied until the signs and symptoms resolve. Research evidence available for this preparation primarily addresses short-term application, generally lasting a few days to a few weeks.

---

Q: Can Compagel be used for symptoms associated with varicose veins?

Studies reviewed in the official documentation have examined the use of topical treatments for localized fluid accumulation (edema) and discomfort linked to superficial vascular issues. This research context is consistent with the type of localized swelling experienced in conditions such as varicose veins.

---

Q: Is there a maximum surface area of the body that Compagel should cover?

Regulatory documents specify a maximum weight of 50 grams of gel per day as the limit for administration. The limitation helps manage the risk of systemic absorption, as applying the gel to large areas may increase the risk of side effects, such as Salicylate poisoning.

---

Q: Does Compagel contain any known allergens like parabens or gluten?

The official documentation lists the complete composition, which includes all the excipients (inactive ingredients) in the gel. A known hypersensitivity or allergy to any of the active substances or excipients is listed as a formal contraindication for use.

---

Q: What is the consistency of Compagel (e.g., thick, runny, sticky)?

Compagel is officially defined by regulators as a clear, hydrophilic gel. A hydrophilic base is formulated to mix easily with water and facilitate the release of the three active pharmaceutical ingredients into the skin.

---

Q: Do you need a prescription to buy Compagel in most places?

The product is officially classified as a veterinary medicinal product. Its specific availability, whether by prescription-only or over-the-counter, is determined by the local regulatory classification (e.g., POM, VET, or OTC) within each country.

---

Q: If I accidentally get Compagel in my eye, what is the recommended action?

Official instructions caution that the product must not contact mucous membranes or the eyes. If accidental contact occurs, official guidance advises that the area should be rinsed thoroughly with water.

---

Q: What happens if a small amount of Compagel is accidentally swallowed?

Official documentation includes mandatory instructions regarding accidental ingestion or overdose. It specifically refers to the potential for acute systemic toxicity, particularly due to the presence of the salicylate component, and includes precautions relating to this type of toxicity.

---

Q: Is it necessary to wash my hands immediately after applying Compagel?

Regulatory documents include specific warnings for the person applying the product. These instructions typically advise that the user should ensure their hands are washed thoroughly immediately after application to prevent accidental transfer of the active ingredients to mucous membranes or eyes.

---

Q: Does Compagel have an odor, and if so, how strong is it?

Official product descriptions list the active components, including Levomenthol. This ingredient is known to impart a distinct and characteristic menthol odor to the gel.

---

Q: Is Compagel designed to absorb completely into the skin or does it leave a residue?

The product is formulated as a hydrophilic gel to facilitate cutaneous application. Official pharmacokinetic data confirms that the concentration of the ingredients in the bloodstream does not reach systemically therapeutic levels.

---

Q: Can I apply a bandage or dressing over the area treated with Compagel?

Regulatory documents advise against applying occlusive dressings or bandages over the area where the product has been used. Using a covering may increase ingredient absorption and heighten the risk of systemic side effects.

How to Store and Dispose of Compagel

Compagel gel must be stored under specific environmental conditions to maintain its labeled stability. Regulatory requirements mandate that the product must be stored at a temperature not exceeding 25 C.

Stability and Child Safety

The product is required to be kept out of the sight and reach of children at all times. The shelf-life of the gel changes once the tube is opened; any remaining product must be discarded after three months of first use.

Official Disposal Instructions

Disposal of any unused Compagel or waste material must comply with the official regulatory guidance for pharmaceutical waste. The product must not be disposed of via wastewater or regular household waste. Instead, it should be disposed of in accordance with local requirements for the collection of unused medicinal products.